Summit Therapeutics (SMMT) Other Gross PP&E Adjustments (2020 - 2026)
Summit Therapeutics filings provide 7 years of Other Gross PP&E Adjustments readings, the most recent being -$19.4 million for Q1 2026.
- Quarterly Other Gross PP&E Adjustments fell 205.43% to -$19.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$19.4 million through Mar 2026, down 205.43% year-over-year, with the annual reading at -$52.8 million for FY2025, 166.9% down from the prior year.
- Other Gross PP&E Adjustments hit -$19.4 million in Q1 2026 for Summit Therapeutics, up from -$52.8 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$2.0 million in Q2 2022 and bottomed at -$52.8 million in Q4 2025.
- Average Other Gross PP&E Adjustments over 5 years is -$10.3 million, with a median of -$6.4 million recorded in 2023.
- The largest annual shift saw Other Gross PP&E Adjustments tumbled 246.85% in 2023 before it skyrocketed 36.3% in 2025.
- Summit Therapeutics' Other Gross PP&E Adjustments stood at -$5.9 million in 2022, then tumbled by 49.39% to -$8.7 million in 2023, then crashed by 126.21% to -$19.8 million in 2024, then plummeted by 166.9% to -$52.8 million in 2025, then surged by 63.24% to -$19.4 million in 2026.
- Per Business Quant, the three most recent readings for SMMT's Other Gross PP&E Adjustments are -$19.4 million (Q1 2026), -$52.8 million (Q4 2025), and -$5.4 million (Q3 2025).